Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A survey of methods for classification of gene expression data using evolutionary algorithms.

Mattias Wahde1, Zoltan Szallasi

  • 1Department of Applied Mechanics, Chalmers University of Technology, SE 412 96, Göteborg, Sweden. mattias.wahde@chalmers.se

Expert Review of Molecular Diagnostics
|December 20, 2005
PubMed
Summary

Evolutionary algorithms (EAs) offer efficient computational techniques for analyzing gene expression data, improving classification accuracy and optimizing gene selection for cancer research. Further clinical validation is needed for identified prognostic markers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RETRACTED: Sharad et al. Analysis of <i>PMEPA1</i> Isoforms (<i>a</i> and <i>b</i>) as Selective Inhibitors of Androgen and TGF-β Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer. <i>Cancers</i> 2019, <i>11</i>, 1995.

Cancers·2026
Same author

Identification of an <i>ERCC2</i> mutation associated mutational signature of nucleotide excision repair deficiency in targeted panel sequencing data.

bioRxiv : the preprint server for biology·2026
Same author

Generation of a comprehensive epigenomic atlas in clear cell renal cell carcinoma informs kidney cancer progression and heritability.

Cell reports·2026
Same author

A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma.

medRxiv : the preprint server for health sciences·2026
Same author

Long-term exposure to the ethanol-derived metabolite acetaldehyde elevates structural genomic alterations but not base substitutions.

Communications biology·2026

Area of Science:

  • Bioinformatics
  • Computational Biology
  • Machine Learning in Genomics

Background:

  • Massively parallel sequencing has led to a surge in biological data, necessitating advanced computational analysis methods.
  • Gene expression data analysis is crucial for understanding complex diseases like cancer.
  • Traditional classification methods may struggle with high-dimensional gene expression datasets.

Purpose of the Study:

  • To review the application of evolutionary algorithms (EAs) for classification using gene expression data.
  • To assess the efficacy of EAs in gene selection and classifier size reduction.
  • To evaluate the impact of EAs on classification accuracy in biological data analysis.

Main Methods:

  • Review of existing studies applying evolutionary algorithms to gene expression data classification.

Related Experiment Videos

  • Introduction to data classification principles and evolutionary algorithms.
  • Analysis of cancer-related datasets utilizing EA-based approaches.

    • Main Results:

    • Evolutionary algorithms demonstrate efficiency in optimal gene selection from large datasets.
    • EAs effectively reduce the number of features required for accurate classification.
    • Classification accuracy significantly improves when using EAs, often in combination with other methods.

    Conclusions:

    • Evolutionary algorithms are a promising computational tool for gene expression data analysis and cancer research.
    • EAs enhance classification performance and enable more parsimonious models.
    • Long-term clinical validation is essential to confirm the utility of EA-identified prognostic markers.